Clinical Trials Logo

Clinical Trial Summary

to review the changes to SLE medications during pregnancy including adherence and non-adherence to the medications and correlate these to the pregnancy outcome and post-partum course of the disease.


Clinical Trial Description

This was a retrospective study of pregnancies in SLE patients. These patients had confirmed SLE diagnosis according to the American College of Rheumatology (ACR) criteria (5). The diagnosis of SLE was confirmed by consultant rheumatologist. These patients were followed up by consultant rheumatologist and obstetrician. The pregnancies' data were curated using the patients' medical files and notes, both paper-based and electronic, antenatal records, rheumatology and hematology clinic notes in addition to delivery and postpartum records. These data were collected including ID numbers, ages, duration of the SLE, their SLE medications before the pregnancy (names, doses and frequency) and whether the SLE was active or not in the 6 months prior to the pregnancy using systemic lupus erythematosus disease activity index (SLEDAI) score. the investigators studied Hydroxychloroquine (HCQ), prednisolone and anti-coagulants (low-dose acetylsalicylic acid; 100 mg orally once daily and low molecular weight heparins (LMWH) Enoxaparin 40 mg subcutaneously once daily) as these were the most commonly used medications. The use of these medications in the different pregnancy periods were noted and analyzed (BPG, before pregnancy; DPG, during pregnancy; PG, pregnancy; PP, post-partum). Changes in these medications were also recorded. The data was then analyzed to find out the rates of changes and discontinuation. The postpartum period was also studied similarly. The investigators correlated these alterations to the following feto-maternal outcomes; miscarriage, preterm delivery, intra-uterine growth restriction (IUGR) and intra-uterine fetal death (IUFD). The 6 months-pre-conceptual SLEDAI score was recorded and investigated in relation to the above mentioned feto-maternal outcomes and postpartum relapse. We divided the pregnancies into 2 groups; Group A, inactive SLE and SLEDAI score of 0-3; Group b, active SLE and SLEDAI score of 4-24. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05176041
Study type Observational
Source University of Jordan
Contact
Status Completed
Phase
Start date September 2016
Completion date January 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT04502823 - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler N/A
Not yet recruiting NCT03625518 - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes Early Phase 1
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Completed NCT01695070 - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Not yet recruiting NCT05284474 - Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler N/A
Completed NCT04289350 - Day to Day Variation in Fetal Heart Rate Variability
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting NCT05023161 - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed NCT02590536 - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction Phase 3
Not yet recruiting NCT05029778 - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve Phase 4
Recruiting NCT05576207 - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR) N/A
Active, not recruiting NCT05160649 - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed NCT02280031 - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Phase 2
Recruiting NCT04389099 - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting NCT06039319 - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting NCT05651347 - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction Phase 3
Recruiting NCT02336243 - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Phase 3
Active, not recruiting NCT01594463 - Routine Ultrasound Screening in the Third Trimester N/A